Sponsor Pipeline

FutureGen Biopharmaceutical (Beijing) Co., Ltd Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
1
Recruiting
2
Phase 3
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-11 NCT07758491 A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma Phase 1/2 Not Yet Recruiting
Active Trials by Phase
Phase 3
2
Phase 1/2
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN)… Locally Advanced Unresectable or Metastatic Gastric Cancer Recruiting
NCT07383922 A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive… Pancreatic Cancer Not Yet Recruiting
Phase 1/2
NCT07623707 A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic… Solid Tumor Not Yet Recruiting
NCT07704866 A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors Claudin 18.2 Not Yet Recruiting
NCT07758491 A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma PTCL Not Yet Recruiting
Disease Areas
Get alerts when FutureGen Biopharmaceutical (Beijing) Co., Ltd's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free